Evidence map›Paper›PMID 40059232›Full record

ArticleAnnals of hematology2025

TP53 deletion is associated with poor survival of adult ALK-positive ALCL patients receiving CHOP-based chemotherapy.

Seiichiro Katagiri, Daigo Akahane, Kunihiko Takeyama, Norihide Sato, Nobuyuki Takayama, Jun Ando, Hideaki Nitta, Masaaki Noguchi, Ken Naganuma, Shuji Momose and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Seiichiro KatagiriDepartment of Hematology, Tokyo Medical University, Tokyo, Japan. katagiri@tokyo-med.ac.jp.
Daigo AkahaneDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Kunihiko TakeyamaDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Norihide SatoDepartment of Hematology, Kyorin University Faculty of Medicine, Tokyo, Japan.
Nobuyuki TakayamaDepartment of Hematology, Kyorin University Faculty of Medicine, Tokyo, Japan.
Jun AndoDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Hideaki NittaDepartment of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Masaaki NoguchiDepartment of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Ken NaganumaDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Shuji MomoseDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Takayuki TabayashiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Masahiro KizakiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Hiroshi KawadaDepartment of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.
Yara Yukie KikutiDepartment of Pathology, Tokai University School of Medicine, Isehara, Japan.
Joaquim CarrerasDepartment of Pathology, Tokai University School of Medicine, Isehara, Japan.
Naoya NakamuraDepartment of Pathology, Tokai University School of Medicine, Isehara, Japan.
Akihiko GotohDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In most cases of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK + ALCL), long-term survival is achieved using CHOP therapy. However, some cases have a poor prognosis. Here, we investigated the clinical impact of TP53 deletion on adult ALK + ALCL patients via a multicenter, retrospective analysis. TP53 deletion was evaluated by fluorescence in situ hybridization (FISH) using paraffin sections of lymphoma samples. To re-evaluate the FISH results, whole genome copy number changes were analyzed in DNA extracted from paraffin sections using OncoScan analysis. Fourteen patients treated with first-line chemotherapy enrolled at six centers were analyzed. All patients received CHOP-based therapy as initial therapy. The 5-year progression-free survival (PFS) and overall survival (OS) of the 14 patients were 28.6% (median 7 months) and 57.1% (median 99 months), respectively. FISH analysis revealed 6 (43%) patients were positive for TP53 deletion (deletion group) and 8 (57%) were negative (non-deletion group). All six patients in the deletion group were diagnosed at an advanced stage; five were refractory to initial treatment, one relapsed after treatment, and all patients died of ALK + ALCL. The median PFS was 3.5 months in the deletion group and 76 months in the non-deletion group. The median OS was 7 months in the deletion group and has yet to be confirmed in the non-deletion group. OncoScan analysis showed TP53 copy number reduction in the deletion group and no TP53 copy number abnormalities in the non-deletion group. This study suggests that TP53 deletion is a poor prognostic factor in ALK + ALCL treated with CHOP-based therapy.

Indexed as

Anaplastic Lymphoma KinaseAntineoplastic Combined Chemotherapy ProtocolsGene DeletionLymphoma, Large-Cell, AnaplasticTumor Suppressor Protein p53AdultAgedCyclophosphamideDoxorubicinFemaleHumansMaleMiddle AgedPrednisonePrognosisRetrospective StudiesALK protein, humanAnaplastic Lymphoma KinaseCyclophosphamideDoxorubicinPrednisoneTP53 protein, humanTumor Suppressor Protein p53VincristineALK-positive ALCLCHOPFISHTP53 deletion

Identifiers

PMID40059232
PMCPMC12031747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.